

were found to have the mutation of tRNA<sup>leu(UUR)</sup>, suggesting that the mitochondrial mutation is frequent among the patients with diabetes and auditory disturbance. However, there have been no reports, to our knowledge, about the real frequency of this mutation in diabetic patients with auditory disturbance.

To investigate whether sensorineural auditory disturbance could be a good index to detect the mitochondrial mutation, we examined the mutation in Japanese type 2 diabetic patients with auditory disturbance. Subjects included 35 Japanese patients (21 men and 14 women; mean [±SD] age, 61.6 ± 12.8 years) with type 2 diabetes (n = 33) or impaired glucose tolerance (n = 2), according to World Health Organization criteria, presenting with hearing loss, which was confirmed to be sensorineural auditory disturbance with audiometry by one of the investigators (H.S.). Genomic DNA was extracted from peripheral leukocytes of the patients and submitted to the detection of an A-to-G transition at the 3243 nucleotide of tRNA<sup>leu(UUR)</sup>, using polymerase chain reaction and restriction fragment length polymorphisms methods with restriction endonuclease *Apa* I. The mutation of the 3243 nucleotide of tRNA<sup>leu(UUR)</sup> was found only in one female patient with type 2 diabetes (2.9%). There was no statistically significant difference (χ<sup>2</sup> test) between this frequency and the reported ones of the mutation among Japanese patients with type 2 diabetes: 0.9% (5) or 2.0% (6).

A previous report (6) showed that 3 out of 5 cases (60%) of Japanese diabetic patients with hearing loss were found to have the mitochondrial DNA mutation. However, all of those patients also had a family history of the association of diabetes and hearing loss. Our result suggests that auditory disturbance is often associated with NIDDM and that mitochondrial DNA mutation is infrequent in Japanese diabetic patients with auditory disturbance.

YASUTOMO FUKUNAGA, MD  
NOBUYUKI AZUMA, MD  
HIROYUKI KOSHIYAMA, MD  
DAISUKE INOUE, MD  
HIROAKI SATO, MD  
YASUNAO YOSHIMASA, MD  
KAZUWA NAKAO, MD

From the Division of Endocrinology and Metabolism, Department of Internal Medicine (Y.F., H.K., D.I.) and Department of Otolaryngology (H.S.), Hyogo Prefectural Amagasaki Hospital, Amagasaki,

Hyogo; and the Department of Medicine and Clinical Science (N.A., Y.Y., K.N.), Kyoto University Graduate School of Medicine, Kyoto, Japan.

Address correspondence to Hiroyuki Koshiyama, MD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo Prefectural Amagasaki Hospital, Amagasaki, Hyogo 660, Japan.

References

1. Di Leo MAS, Monaco ML, Di Nardo W, Greco AV, Cercone S, Paludetti G, Ciervo A, Ghirlanda G: Cochlear dysfunction in IDDM patients with subclinical peripheral neuropathy. *Diabetes Care* 20:824–828, 1997
2. Van den Ouweland JMW, Lemekes HHPJ, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PAA, van de Kamp JJP, Maassen JA: Mutation in mitochondrial tRNA gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. *Nat Genet* 1:369–371, 1992
3. Awata T, Matsumoto T, Iwamoto Y, Matsuda A, Kuzuya T, Saito T: Japanese case of diabetes mellitus and deafness with mutation in mitochondrial tRNA<sup>leu(UUR)</sup> gene. *Lancet* 341:1291–1292, 1993
4. Vionnet N, Passa P, Froguel P: Prevalence of mitochondrial gene mutations in families with diabetes mellitus. *Lancet* 342:1429–1430, 1993
5. Otabe S, Sakura H, Shimokawa K, Mori Y, Kadowaki H, Yasuda K, Nonaka K, Hagura R, Akanuma Y, Yazaki Y, Kadowaki T: The prevalence of the diabetic patients with a mutation in the mitochondrial gene in Japan. *J Clin Endocrinol Metab* 79:768–771, 1994
6. Kadowaki T, Kadowaki H, Mori Y, Tobe K, Saruta R, Suzuki Y, Tanabe Y, Sakura H, Awata T, Goto Y-I, Hayakawa T, Matsuoka K, Kawamori R, Kamada T, Horai S, Nonaka I, Hagura R, Akanuma Y, Yazaki Y: A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. *N Engl J Med* 330:962–968, 1994

**Response to Fukunaga et al.**

Fukunaga et al. found that the mutation at np 3243 in the mitochondrial tRNA<sup>LEU(UUR)</sup> gene was rare in Japanese nonselected type 2 diabetic patients with hearing loss. Although this point mutation is commonly present in patients with the syndrome of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (1,2), the presence of the 3243 mutation in diabetic patients with maternal inheritance and

deafness was noted in a group of Dutch and Japanese populations (3,4). It is clear that no obvious relationship between the 3243 mutation and the onset or the type of diabetes is evident, as postulated by Maassen and Kadowaki (5). The low prevalence of the tRNA<sup>LEU(UUR)</sup> mutation is in keeping with some studies (6–8) where the mutation is likely to account for <1% of type 2 diabetes. As concerns the effect of the tRNA<sup>LEU(UUR)</sup> gene mutation on the nature of diabetes (i.e., type 2 diabetes), the situation is still less clear.

Although in our study our type 1 diabetic patients were not tested for the tRNA<sup>LEU(UUR)</sup> gene mutation, they underwent an audiological examination to exclude the presence of hearing loss before performing the evoked otoacoustic emissions. Thus, the impairment of cochlear receptor function found in some of our patients may indicate an early damage of peripheral nervous system that does not necessarily lead to deafness. Moreover, the finding of mitochondrial DNA mutation by using polymerase chain reaction techniques in peripheral leukocytes may not accurately reflect the number of mutated mitochondria in β-cells, which play an important role in pathogenesis of type 1 diabetes.

An interesting observation is that we showed that no mother of our type 1 diabetic patients with cochlear dysfunction was affected by diabetes. Two of our patients had diabetic fathers (type 1 diabetes in one case and type 2 in the other). We conclude that the tRNA<sup>LEU(UUR)</sup> mutation does not have a prominent place in the association with type 1 diabetes.

MAURO A.S. DI LEO, MD  
STEFANIA CERCONE, MD  
ALDO V. GRECO, MD  
GIOVANNI GHIRLANDA, MD

From the Department of Internal and Geriatric Medicine, Catholic University, Rome, Italy.

Address correspondence to Mauro A.S. Di Leo, MD, Department of Internal Medicine, Catholic University, Largo A. Gemelli 8, 00168 Rome, Italy.

References

1. Kobayashi Y, Momoi MY, Tominaga K: A point mutation in the mitochondrial tRNA<sup>LEU(UUR)</sup> gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes). *Biochem Biophys Res Commun* 173:816–822, 1990
2. Goto Y, Nonaka I, Horai S: A mutation in the tRNA<sup>LEU(UUR)</sup> gene associated with the MELAS subgroup of mitochondrial

encephalopathies. *Nature* 348:651–653, 1990

3. Katagiri H, Asana T, Ishihara H, Inukai K, Asai M, Yamanouchi T, Tsukada R, Kikuchi M, Kitaoka H, Oshsawa N, Yazaki Y, Oka Y: Mitochondrial diabetes mellitus: prevalence and clinical characterization of diabetes due to mitochondrial tRNA<sup>LEU(UUR)</sup> gene mutation in Japanese patients. *Diabetologia* 37:504–510, 1994
4. Van den Ouweland JMW, Lemkes HHPJ, Trembath RC, Ross R, Velho G, Cohen D, Froguel P, Maassen JA: Maternally inher-

ited diabetes and deafness is a distinct subtype of diabetes and associated with a single point mutation in mitochondrial tRNA<sup>LEU(UUR)</sup> gene. *Diabetes* 43:746–751, 1994

5. Maassen JA, Kadowaki T: Maternally inherited diabetes and deafness: a new diabetes subtype. *Diabetologia* 39:375–382, 1996
6. Elbein SC, Hoffman MD: Role of mitochondrial DNA tRNA leucine and glucagon receptor missense mutations in Utah white diabetic patients. *Diabetes Care*

19:507–508, 1996

7. Rigoli L, Di Benedetto A, Romano G, Corica F, Cucinotta D: Mitochondrial DNA [tRNA<sup>LEU(UUR)</sup>] mutation in a southern Italian diabetic population. *Diabetes Care* 20:674–675, 1997
8. Saker PJ, Hatteraley AT, Barrow B, Hammeraley MS, Horton V, Gillmer MD, Turner RC: UKPDS 21: low prevalence of the mitochondrial transfer RNA gene (tRNA<sup>LEU(UUR)</sup>) mutation at position 3243 bp in UK Caucasian type 2 diabetic patients. *Diabet Med* 14:42–45, 1997

## Erratum

Tuomilehto J, Borch-Johnsen K, Molarius A, Jormanainen V, Lounamaa R, Grönhagen-Riska C, Reunanen A, Sarti C: The unchanging incidence of hospitalization for diabetic nephropathy in a population-based cohort of IDDM patients in Finland. *Diabetes Care* 20:1081–1086, 1997

In the above article, the wrong figure was printed as Fig. 3. The correct Fig. 3 and legend are provided below.




Figure 3—Cumulative incidence of hospitalization for diabetic nephropathy according to age at onset of IDDM: ages 0–4, 5–9, 10–14, and 15–17 years.